HLA-B27 and Autoimmune Disease: What the Gene Reveals

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on immune & autoimmune genetics. Browse all Immune & Autoimmune Genetics education

HLA-B27 is one of the most recognized genetic markers in rheumatology. It is a specific variant of the HLA-B gene, part of the human leukocyte antigen system that helps the immune system tell “self” from “foreign.” Carrying HLA-B27 raises the likelihood of certain autoimmune and inflammatory conditions — though most people who carry it never develop any disease at all.

What HLA-B27 is

The HLA-B gene encodes a major histocompatibility complex (MHC) class I protein that sits on the surface of nearly every cell and presents small protein fragments to immune cells. HLA-B27 is one of many possible versions of this gene. Its job is normal immune surveillance; the trouble arises when, in a susceptible person, this presentation process appears to misfire and drive inflammation against the body’s own tissues.

Conditions linked to HLA-B27

The strongest association is with ankylosing spondylitis, a form of inflammatory arthritis affecting the spine and sacroiliac joints. HLA-B27 is also linked to reactive arthritis, acute anterior uveitis (a painful inflammation of the eye), psoriatic arthritis, and arthritis associated with inflammatory bowel disease. Together these fall under the umbrella of spondyloarthritis. The marker is a risk factor, not a guarantee — and its absence does not rule these conditions out.

How HLA-B27 may drive autoimmunity

The exact mechanism is still being worked out. Leading hypotheses include the “arthritogenic peptide” idea — that HLA-B27 presents a self-peptide the immune system mistakes for a threat — and the tendency of the HLA-B27 protein to misfold, triggering a cellular stress response. Importantly, the ERAP1 gene, which trims peptides before they are loaded onto HLA-B27, interacts with it: certain ERAP1 variants raise ankylosing spondylitis risk mainly in people who are HLA-B27 positive.

Prevalence and risk in context

Roughly 6 to 8 percent of people of European descent carry HLA-B27, yet only a small fraction develop spondyloarthritis. That gap is the key point: the marker shifts probability, it does not determine outcome. Family history, other genes such as ERAP1, and environmental triggers all contribute.

The PlexusDx Precision Peptide Genetic Test analyzes your DNA across 14 pathways, 49 peptides, 150+ genetic insights, including immune-signaling and inflammatory pathways. It does not diagnose ankylosing spondylitis or any autoimmune disease. It provides pathway-level context about your biology that supports — but never replaces — a rheumatologist’s clinical assessment.

Testing and what a result means

A positive HLA-B27 result confirms that you carry the marker; it does not mean you have or will develop an autoimmune condition. Clinicians interpret it alongside symptoms, imaging, and inflammatory markers — never in isolation. A negative result does not exclude spondyloarthritis, since a meaningful share of cases occur in HLA-B27-negative individuals. Genetic information is one input into a clinical picture that only a provider can assemble.

Frequently Asked Questions

Does having HLA-B27 mean I will get an autoimmune disease?

No. Most people who carry HLA-B27 never develop an autoimmune condition. The marker raises the statistical likelihood of spondyloarthritis, including ankylosing spondylitis and acute anterior uveitis, but does not cause disease on its own. Symptoms, imaging, and a rheumatologist’s evaluation determine whether a condition is actually present.

Which diseases are most associated with HLA-B27?

Ankylosing spondylitis has the strongest link, followed by reactive arthritis, acute anterior uveitis, psoriatic arthritis, and arthritis tied to inflammatory bowel disease. These related conditions are grouped as spondyloarthritis. HLA-B27 is a shared risk factor across them, though each has its own additional genetic and environmental contributors.

Can genetic testing diagnose ankylosing spondylitis?

No. Genetic testing cannot diagnose ankylosing spondylitis or any autoimmune disease. Detecting HLA-B27 only confirms you carry the marker. Diagnosis requires clinical evaluation, imaging such as X-rays or MRI, and blood tests interpreted by a provider. Genetic context adds a piece of the picture, not a conclusion.

What does the ERAP1 gene have to do with HLA-B27?

ERAP1 trims protein fragments before they are presented by HLA-B27. Certain ERAP1 variants increase ankylosing spondylitis risk specifically in people who are HLA-B27 positive, showing how the two genes interact. This gene-gene relationship helps explain why not everyone carrying HLA-B27 develops disease.

Your genes shape immune-signaling and inflammatory pathways. Take the Precision Peptide Genetic Test to understand your pathway-level biology, then discuss it with a qualified provider. It is educational context about your body — not a diagnosis of any autoimmune condition.

Disclaimer: The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

This article is part of the PlexusDx Education Hub. Browse all Immune & Autoimmune Genetics education